Laboratorios Farmaceuticos Rovi (XMAD:ROVI) ROCE % : 43.83% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Laboratorios Farmaceuticos Rovi's annualized ROCE % for the quarter that ended in Dec. 2023 was 43.83%.

Laboratorios Farmaceuticos Rovi ROCE % Historical Data

The historical data trend for Laboratorios Farmaceuticos Rovi's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorios Farmaceuticos Rovi ROCE % Chart

Laboratorios Farmaceuticos Rovi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

11.82

17.15

36.89

45.88

37.32

Laboratorios Farmaceuticos Rovi Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															40.38	16.48	46.18	43.83	12.88

Laboratorios Farmaceuticos Rovi ROCE % Calculation

Laboratorios Farmaceuticos Rovi's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	221.075	/	( ( (878.703 - 293.887)	+	(799.884 - 199.843) )	/ 2 )
	=	221.075	/	( (584.816	+	600.041)	/ 2 )
	=	221.075	/	592.4285
	=	37.32 %

Laboratorios Farmaceuticos Rovi's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	265.164	/	( ( (830.725 - 220.774)	+	(799.884 - 199.843) )	/ 2 )
	=	265.164	/	( ( 609.951	+	600.041 )	/ 2 )
	=	265.164	/	604.996
	=	43.83 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Laboratorios Farmaceuticos Rovi ROCE % Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ROVI:Mexico ROVIe:UK 41L:Germany

Address

Julian Camarillo, 35, Madrid, ESP, 28037

Website

https://www.rovi.es

Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.